David Roman
Stock Analyst at Goldman Sachs
(1.61)
# 2,534
Out of 4,667 analysts
21
Total ratings
27.27%
Success rate
-5.3%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Initiates: Neutral | $108 | $102.96 | +4.90% | 1 | Nov 15, 2024 | |
| TDOC Teladoc Health | Initiates: Buy | $14 | $9.00 | +55.56% | 1 | Nov 15, 2024 | |
| DOCS Doximity | Initiates: Neutral | $58 | $49.90 | +16.23% | 1 | Nov 15, 2024 | |
| LIVN LivaNova | Initiates: Buy | $65 | $50.05 | +29.87% | 1 | Oct 4, 2024 | |
| IRTC iRhythm Technologies | Initiates: Neutral | $78 | $73.74 | +5.78% | 1 | Oct 4, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Neutral | $46 | $30.15 | +52.57% | 1 | Oct 4, 2024 | |
| SOLV Solventum | Maintains: Sell | $48 → $54 | $68.39 | -21.04% | 3 | Aug 12, 2024 | |
| BAX Baxter International | Maintains: Neutral | $36 → $40 | $32.63 | +22.59% | 2 | Aug 8, 2024 | |
| EW Edwards Lifesciences | Maintains: Buy | $107 → $91 | $69.54 | +30.86% | 2 | Jul 26, 2024 | |
| BSX Boston Scientific | Initiates: Buy | $90 | $90.17 | -0.19% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $372 | $385.68 | -3.55% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $541.82 | -7.72% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $121 | $115.93 | +4.37% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $222.39 | +23.21% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $129 | $109.27 | +18.06% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $84.11 | -1.32% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $87 | $84.90 | +2.47% | 1 | May 30, 2024 |
HealthEquity
Nov 15, 2024
Initiates: Neutral
Price Target: $108
Current: $102.96
Upside: +4.90%
Teladoc Health
Nov 15, 2024
Initiates: Buy
Price Target: $14
Current: $9.00
Upside: +55.56%
Doximity
Nov 15, 2024
Initiates: Neutral
Price Target: $58
Current: $49.90
Upside: +16.23%
LivaNova
Oct 4, 2024
Initiates: Buy
Price Target: $65
Current: $50.05
Upside: +29.87%
iRhythm Technologies
Oct 4, 2024
Initiates: Neutral
Price Target: $78
Current: $73.74
Upside: +5.78%
Tandem Diabetes Care
Oct 4, 2024
Initiates: Neutral
Price Target: $46
Current: $30.15
Upside: +52.57%
Solventum
Aug 12, 2024
Maintains: Sell
Price Target: $48 → $54
Current: $68.39
Upside: -21.04%
Baxter International
Aug 8, 2024
Maintains: Neutral
Price Target: $36 → $40
Current: $32.63
Upside: +22.59%
Edwards Lifesciences
Jul 26, 2024
Maintains: Buy
Price Target: $107 → $91
Current: $69.54
Upside: +30.86%
Boston Scientific
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $90.17
Upside: -0.19%
May 30, 2024
Initiates: Neutral
Price Target: $372
Current: $385.68
Upside: -3.55%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $541.82
Upside: -7.72%
May 30, 2024
Initiates: Buy
Price Target: $121
Current: $115.93
Upside: +4.37%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $222.39
Upside: +23.21%
May 30, 2024
Initiates: Neutral
Price Target: $129
Current: $109.27
Upside: +18.06%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $84.11
Upside: -1.32%
May 30, 2024
Initiates: Neutral
Price Target: $87
Current: $84.90
Upside: +2.47%